HRT patches to treat prostate cancer – here’s how it works
Analysis Summary
- Propaganda Score
- 0% (confidence: 95%)
- Summary
- A UK trial found that hormone patches used for menopause symptoms in women can treat advanced prostate cancer in men as effectively as traditional hormone injections, but with fewer severe side effects like hot flashes and bone loss. The study suggests these patches could offer a more tolerable treatment option for prostate cancer patients.
Fact-Check Results
“Women’s HRT patches can treat prostate cancer just as effectively as standard hormone injections”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to confirm or refute effectiveness of HRT patches vs injections for prostate cancer
“The finding could change how men with prostate cancer that has spread beyond the gland are treated for years to come”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to support or contradict potential treatment paradigm shifts
“Standard treatment has long relied on shutting down testosterone through regular injections”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to verify standard treatment methods
“In the new trial, more than 1,300 men, with an average age of about 72, were randomly allocated to either the standard hormone injections or to skin patches”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to confirm trial demographics
“After three years, the proportion of men alive without the cancer progressing was almost identical in the two groups: 87% in the patch arm and 86% with injections”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to verify survival statistics
“Almost nine in ten men on injections reported hot flushes. Among those wearing patches, less than half did”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to confirm hot flush incidence rates
“Bone health also favoured the patches, with fractures roughly twice as common in the injection group”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to verify fracture rates between treatments
“More than 80% developed breast tissue swelling, compared with about 40% of those on injections”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to confirm gynaecomastia incidence
“The trial is part of a broader shift towards re-examining assumptions in oncology”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to verify oncology treatment paradigm shifts
“Regulatory approval is still needed for oestradiol patches specifically for prostate cancer”
❓
INSUFFICIENT EVIDENCE
— No evidence in archive to confirm regulatory approval status